Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Commentary|Articles|June 11, 2026
Head and Neck Oncologists Highlight Practice-Informing Research From ASCO 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Tracy Ann Politowicz
Experts highlight the most interesting and potentially paradigm-shifting head and neck cancer data to come out of the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
During the
Related to this article
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.
The phase 3 ECHO trial confirmed a durable progression-free survival benefit with frontline acalabrutinib-based therapy in mantle cell lymphoma.
Advertisement
Advertisement